tmem38a Antibody

What is TMEM38A and why is it significant in molecular and cellular research?

TMEM38A (Transmembrane Protein 38A) represents one of two identified trimeric intracellular cation (TRIC) channel subtypes, also known as TRIC-A, Mitsugumin-33A, or sarcoplasmic reticulum protein 27 (SPR-27). The protein is primarily expressed in excitable tissues including striated muscle and brain, where it localizes to the sarcoplasmic reticulum membrane . Functionally, TMEM38A serves as a counter-ion channel that operates in coordination with calcium release from intracellular stores, maintaining ionic balance during calcium flux events . The significance of this protein becomes particularly evident when examining knockout models, as mice deficient in both TMEM38A and TMEM38B experience embryonic cardiac failure with severe dysfunction in SR calcium handling, weakened calcium release, and reduced potassium permeability . These phenotypes demonstrate that TRIC channels are essential for proper excitation-contraction coupling in muscle tissues. Additionally, TMEM38A can function in conjunction with junctophilin proteins to support efficient ryanodine receptor-mediated calcium release in muscle cells . Most recently, TMEM38A has gained attention for its association with radiotherapy sensitivity in cervical cancer, suggesting potential clinical applications beyond its basic physiological roles .

What types of TMEM38A antibodies are currently available for scientific applications?

A variety of TMEM38A antibodies have been developed for research purposes, differing in their target epitopes, host species, and validated applications. The following table summarizes key antibodies currently available:

For experimental validation, researchers have identified suitable positive controls, with rat skeletal muscle tissue lysate frequently recommended as an appropriate standard . When selecting an antibody, researchers should consider the specific application requirements, species of interest, and target epitope accessibility in their experimental system. Some antibodies, such as PA5-20858, can be used in conjunction with specific blocking peptides (e.g., PEP-0972) for validation studies .

What fundamental methodological considerations apply when using TMEM38A antibodies?

When utilizing TMEM38A antibodies for scientific research, several methodological considerations must be addressed to ensure reliable and reproducible results. For western blotting applications, researchers should be aware that TMEM38A has a molecular weight of approximately 27 kDa and optimal detection typically requires loading 30-50 μg of protein per lane . Membrane protein extraction buffers containing mild detergents (0.5-1% digitonin or 0.5% DDM) are recommended to preserve the native conformation of TMEM38A . For immunohistochemical applications, specific antigen retrieval protocols have been established, with TE buffer at pH 9.0 generally providing superior results, though citrate buffer at pH 6.0 can serve as an alternative . When performing immunohistochemistry on paraffin-embedded tissues, a detailed protocol involves deparaffinization in xylene (10 minutes), dehydration in graded alcohols, blocking with goat serum (30 minutes at 37°C), and overnight incubation with primary antibody (typically at 1:100 dilution) at 4°C . For signal development, diaminobenzidine (DAB) chromogenic kit followed by hematoxylin counterstaining has been successfully employed .

Quantification approaches vary by application, with western blots typically normalized to housekeeping proteins and immunohistochemical analysis involving calculation of positive expression rate (positive cells/total cells ×100%) . For experimental validation, multiple technical replicates (minimum of three independent experiments) should be performed to ensure statistical reliability . Finally, appropriate statistical analysis methods include t-tests for normally distributed data with homogeneous variances and Wilcoxon rank-sum tests for non-parametric comparisons, with p<0.05 considered statistically significant .

How can TMEM38A antibody specificity be rigorously validated in experimental systems?

Rigorous validation of TMEM38A antibody specificity is essential for generating reliable scientific data. A comprehensive validation strategy should employ multiple complementary approaches. First, genetic validation represents the gold standard, utilizing TMEM38A knockout or knockdown models to confirm antibody specificity . This can be accomplished through CRISPR-Cas9 gene editing, siRNA-mediated knockdown, or utilizing tissues from knockout animal models. A specific signal in wild-type samples that disappears in knockout samples provides strong evidence for antibody specificity. Second, peptide competition assays offer another powerful validation approach . This involves pre-incubating the antibody with the immunizing peptide (such as PEP-0972 for PA5-20858) at varying concentrations (1-10 μg/ml) before application in the intended assay . Abolishment of signal indicates specific binding to the target epitope. Third, cross-antibody validation compares staining patterns using multiple antibodies targeting different epitopes of TMEM38A. Concordant patterns across different antibodies increase confidence in specificity.

Fourth, orthogonal validation correlates protein detection with mRNA expression levels using techniques like RT-qPCR or RNA-seq . Fifth, known expression pattern validation confirms that detected patterns match established TMEM38A distribution, with expected high expression in skeletal muscle and brain tissues . Sixth, recombinant protein controls test the antibody against purified recombinant TMEM38A and related proteins (TMEM38B) to assess specificity and potential cross-reactivity. Finally, employing blocking peptides specific to the antibody in question provides additional confirmation of binding specificity . Implementing this multi-faceted validation strategy significantly increases confidence in antibody specificity and experimental results.

What experimental designs are optimal for investigating TMEM38A's role in calcium signaling pathways?

Investigating TMEM38A's role in calcium signaling requires specialized experimental designs that integrate multiple techniques. An optimal approach begins with functional calcium imaging, combining TMEM38A immunolabeling with calcium dynamics measurements. This can involve using ratiometric calcium indicators like Fura-2 or genetically encoded calcium indicators (GCaMP variants) to monitor real-time calcium flux while modulating TMEM38A expression or activity . Subcellular fractionation protocols should be implemented to isolate sarcoplasmic/endoplasmic reticulum membranes where TMEM38A resides, allowing biochemical characterization of protein complexes involved in calcium handling . Fraction purity must be verified using established markers such as SERCA for SR/ER membranes.

For protein interaction studies, co-immunoprecipitation experiments should employ membrane-compatible detergents (e.g., digitonin) that preserve native protein interactions . Proximity ligation assays (PLA) offer an alternative approach for detecting in situ protein interactions with spatial resolution. When examining functional consequences, pharmacological manipulations using modulators of calcium signaling (thapsigargin for SERCA inhibition, ryanodine for RyR modulation) can reveal how TMEM38A integrates with the broader calcium handling machinery . Parallel assessment of TMEM38A expression/localization and calcium signaling parameters (store content, release kinetics, SOCE magnitude) helps establish mechanistic relationships. For advanced studies, genetic approaches modulating TMEM38A expression (overexpression, knockdown, or domain-specific mutations) combined with functional calcium measurements provide causal evidence for its roles. Correlation with other calcium handling proteins (JPH1/2, RyR1/2, SERCA) through multiplex imaging or sequential immunoblotting contextualizes TMEM38A's position within the calcium signaling network .

How does TMEM38A interact with radiotherapy response mechanisms in cancer cells?

The protein also shows significant correlations with immune cell infiltration patterns, particularly with natural killer cells, neutrophils, CD4+ T cells, and Type 2 T helper cells (p<0.01) . This suggests TMEM38A may influence radiotherapy efficacy partly through modulation of the tumor immune microenvironment. Expression analysis further revealed associations with numerous immune checkpoint molecules, including CD44, TNFSF14, and TNFRSF18, pointing to potential immunomodulatory functions . Additionally, TMEM38A shows connections to cellular pathways involved in reactive oxygen species metabolism, xenobiotic metabolism, E2F targets, G2M checkpoint regulation, and mitotic spindle formation—all processes relevant to radiation response . Notably, unsupervised clustering analysis using TMEM38A and other radiotherapy-associated genes defined three distinct molecular subtypes of cervical cancer with different treatment sensitivities . The development of a neural network-based predictive model incorporating TMEM38A expression achieved impressive predictive power for radiotherapy response (AUC = 0.936), highlighting its potential as a biomarker .

What protocols should be followed for TMEM38A detection in cancer tissue samples?

For optimal detection of TMEM38A in cancer tissue samples, specific protocols have been validated and should be followed meticulously. When working with paraffin-embedded tumor tissues, a detailed immunohistochemical protocol begins with deparaffinization in xylene for 10 minutes, followed by dehydration through a graded alcohol series and rinsing with distilled water . Antigen retrieval is a critical step, with TE buffer at pH 9.0 generally recommended, though citrate buffer at pH 6.0 can serve as an alternative depending on tissue type and fixation conditions . Following antigen retrieval, sections should be incubated with goat serum for 30 minutes at 37°C to prevent non-specific binding . Primary antibody incubation should be conducted overnight at 4°C, with a 1:100 dilution of TMEM38A antibody (validated antibodies include those from Sino Biological) . After thorough washing (three times with PBS, 5 minutes each), sections should be incubated with appropriate secondary antibody for 90 minutes at 37°C . Signal development using diaminobenzidine (DAB) chromogenic kit followed by hematoxylin counterstaining provides optimal visualization .

For quantification, positive expression rate calculation (positive cells/total number of cells ×100%) has been established as a reliable metric, with assessment performed across five randomly selected fields for each sample . When analyzing results statistically, researchers should employ t-tests for normally distributed data or Wilcoxon rank-sum tests for non-parametric data . For correlative studies, Spearman correlation analysis can be used to investigate relationships between TMEM38A expression and other parameters, such as immune cell infiltration markers . For western blotting applications in cancer tissues, optimized protocols include homogenization in buffers containing 20 mM Tris-HCl (pH 7.4), 1% Triton X-100, 150 mM NaCl, and 1 mM EDTA with complete protease inhibitors . Researchers should ensure multiple biological replicates and appropriate positive controls (such as skeletal muscle lysate) to validate findings .

How can TMEM38A antibodies be optimized for use in muscle tissue studies?

Optimizing TMEM38A antibody protocols for muscle tissue studies requires consideration of tissue-specific factors and target protein characteristics. Muscle tissues present unique challenges due to their dense protein content and specialized membrane systems. For immunohistochemical and immunofluorescence applications, tissue preparation is crucial—fresh-frozen samples should be snap-frozen in isopentane cooled with liquid nitrogen, while fixed samples benefit from 4% paraformaldehyde for 2-4 hours (avoiding over-fixation which can mask epitopes) . Sectioning should be performed at 5-8 μm for light microscopy or 10-15 μm for confocal microscopy, with both longitudinal and cross-sectional orientations providing complementary information .

For western blotting applications, specialized extraction protocols yield superior results. Homogenization buffers containing 20 mM Tris-HCl (pH 7.4), 1% Triton X-100, 150 mM NaCl, and 1 mM EDTA with protease inhibitors effectively solubilize TMEM38A while maintaining protein integrity . Loading 30-50 μg protein per lane typically provides optimal signal, with low-methanol (10%) PVDF transfer at 30V overnight improving transfer efficiency for membrane proteins like TMEM38A . Antibody dilutions should be optimized, with 1:1000 for western blotting and 1:100-1:200 for immunostaining typically providing good results . Rat skeletal muscle tissue lysate serves as an excellent positive control for validation studies .

For subcellular localization studies, co-staining with sarcoplasmic reticulum markers such as SERCA or ryanodine receptors helps confirm the expected localization pattern . Subcellular fractionation can further enhance detection sensitivity, with differential centrifugation protocols (1,000g → 10,000g → 100,000g) yielding microsomal fractions enriched for TMEM38A . Fraction purity should be verified using established organelle markers. For functional correlation studies, combining TMEM38A detection with calcium imaging in isolated muscle fibers provides valuable insights into the protein's physiological roles .

What approaches facilitate studying TMEM38A's potential role as a biomarker for radiation response?

Investigating TMEM38A's potential as a biomarker for radiation response requires integrated approaches spanning clinical samples, molecular analyses, and functional validation. A comprehensive strategy begins with stratified patient cohort analysis, comparing TMEM38A expression between radiotherapy-sensitive and radiotherapy-resistant tumors using validated immunohistochemical protocols . Quantitative assessment through positive expression rate calculations (positive cells/total cells ×100%) provides a standardized metric for comparison . For advanced quantification, H-score methods incorporating both staining intensity and percentage of positive cells offer more nuanced analysis. Digital pathology approaches using automated imaging and analysis systems can reduce subjective bias and increase reproducibility.

Immune correlative studies represent an emerging direction, assessing relationships between TMEM38A expression and tumor immune microenvironment components including natural killer cells, neutrophils, CD4+ T cells, and immune checkpoint molecules . For translational applications, developing standardized detection methods with defined cutoff values for "high" versus "low" expression facilitates clinical implementation. Finally, predictive model development incorporating TMEM38A with other biomarkers using machine learning approaches (neural networks, random forests) can enhance predictive power for patient stratification and treatment decisions .

What are common challenges in TMEM38A antibody applications and their solutions?

Researchers working with TMEM38A antibodies frequently encounter several technical challenges that require specific troubleshooting approaches. One common issue is weak or absent signal in western blot applications, which may result from insufficient protein loading, inefficient transfer of membrane proteins, or epitope masking. To address this, increasing protein loading to 50-100 μg per lane, employing specialized membrane protein transfer protocols (low SDS, low methanol), and testing antibodies targeting different epitopes can improve detection . For particularly difficult samples, signal enhancement systems or more sensitive detection reagents may be necessary. Another frequent challenge is high background in immunostaining applications, which can obscure specific signals. Implementing more stringent blocking conditions (longer blocking times of 2+ hours, higher serum concentrations of 5-10%), including 0.1-0.3% Triton X-100 in antibody dilution buffers, and employing more thorough washing steps can significantly reduce background .

Detection of multiple bands in western blots presents another common problem, making data interpretation difficult. Researchers should verify the expected molecular weight (approximately 27 kDa for TMEM38A) and implement peptide competition controls to identify specific bands . Using fresh samples with complete protease inhibitor cocktails minimizes degradation products that can appear as additional bands . When working with tissues showing variable expression levels, inconsistent staining can occur across samples. Standardizing fixation protocols, optimizing antigen retrieval conditions (testing both pH 6.0 and pH 9.0 buffers), and including positive control tissues in each experiment ensures reliable comparison . For cross-reactivity concerns, particularly with the related protein TMEM38B, validation in knockout/knockdown systems and peptide competition assays provide definitive evidence of specificity . Finally, when quantifying results, normalization to appropriate loading controls (β-actin for total lysates, Na+/K+-ATPase for membrane fractions) and use of standard curves with recombinant proteins or calibrated control samples enables accurate comparative analysis .

What factors influence TMEM38A detection in different experimental systems?

Multiple factors significantly impact TMEM38A detection across experimental systems, requiring careful consideration during study design and execution. Tissue-specific expression patterns represent a primary consideration, with TMEM38A showing highest natural expression in excitable tissues like skeletal muscle and brain, while expression in other tissues may be considerably lower . This necessitates optimization of detection methods based on expected expression levels in the tissue of interest. Sample preparation methodology dramatically affects detection sensitivity—for fresh-frozen tissues, rapid freezing in isopentane cooled with liquid nitrogen preserves protein integrity, while fixed samples benefit from moderate fixation (4% paraformaldehyde for 2-4 hours) to avoid epitope masking through over-fixation . For membrane proteins like TMEM38A, extraction buffer composition significantly impacts recovery, with buffers containing mild detergents (0.5-1% digitonin or 0.5% DDM) better preserving native conformation compared to more harsh detergents like SDS .

Antibody selection represents another critical factor, with different antibodies targeting various epitopes (N-terminal, C-terminal, cytoplasmic domain) showing variable performance across applications . Researchers should validate antibodies for their specific application and tissue type. Technical parameters including antibody dilution (typically 1:1000 for WB, 1:100-1:200 for IHC/IF), incubation conditions (overnight at 4°C generally yielding better results than shorter incubations at room temperature), and detection systems (enhanced chemiluminescence for WB, fluorescent secondaries for IF) all require optimization for each experimental system . For western blotting, transfer conditions significantly impact results, with low-methanol (10%) PVDF transfer at 30V overnight improving detection of membrane proteins compared to standard protocols . Antigen retrieval methods for fixed tissues show application-specific effectiveness, with TE buffer at pH 9.0 generally recommended for TMEM38A detection, though citrate buffer at pH 6.0 remains a viable alternative depending on tissue type and fixation conditions . Finally, quantification approaches should be standardized, using consistent methodologies for calculating relative expression levels, positive cell percentages, or staining intensities across experimental groups .

How has TMEM38A emerged as a potential biomarker in cancer radiotherapy research?

Recent investigations have positioned TMEM38A as a promising biomarker for radiotherapy response, particularly in cervical cancer. Through rigorous screening of the TCGA database, researchers identified differentially expressed genes between radiotherapy-sensitive and radiotherapy-resistant cervical cancer patients . Advanced machine learning techniques including least absolute shrinkage and selection operator regression and random forest analysis refined this gene set, ultimately identifying seven crucial genes strongly associated with radiotherapy sensitivity: GJA3, TMEM38A, ID4, CDHR1, SLC10A4, KCNG1, and HMGCS2 . Among these, TMEM38A, a mitochondrial gene, exhibited the highest degree of correlation with radiotherapy sensitivity, suggesting its potential as a key biomarker . Enrichment analysis revealed significant associations between these genes and prominent signaling pathways, including the p53 signaling pathway, KRAS signaling pathway, and PI3K/AKT/MTOR pathway, providing mechanistic insights into their roles in treatment response .

Unsupervised clustering analysis using these seven genes categorized cervical cancer patients into three distinct molecular subtypes with different expression patterns and treatment sensitivities . Notably, TMEM38A expression was significantly higher in Cluster C compared to Clusters A and B, correlating with improved radiotherapy response . A neural network-based predictive model incorporating TMEM38A expression achieved impressive predictive power for radiotherapy sensitivity (AUC = 0.936) . Experimental validation through RT-qPCR and immunohistochemistry confirmed increased expression of TMEM38A in radiotherapy-sensitive cervical cancer tissues . The protein's expression also showed significant correlations with immune cell infiltration, including natural killer cells, neutrophils, and CD4+ T cells, suggesting potential immunomodulatory functions that may contribute to radiation response . These findings collectively establish TMEM38A as a promising biomarker with potential applications in patient stratification, treatment selection, and development of novel therapeutic approaches to overcome radiotherapy resistance .

What are the emerging applications of TMEM38A antibodies in diverse research fields?

TMEM38A antibodies are finding increasingly diverse applications across multiple research domains, expanding beyond traditional calcium signaling studies. In cancer biology, these antibodies are being employed to evaluate TMEM38A's potential as a biomarker for radiotherapy sensitivity, particularly in cervical cancer . Immunohistochemical analysis of tumor specimens allows researchers to correlate TMEM38A expression with treatment outcomes and patient survival, potentially informing clinical decision-making . Additionally, TMEM38A antibodies are facilitating investigations into the protein's interactions with critical signaling networks, including p53, KRAS, and PI3K/AKT/mTOR pathways, which have broad implications for cancer biology and therapeutics . In the field of developmental biology, TMEM38A antibodies enable studies of embryonic development and organogenesis, particularly cardiac development where TMEM38A plays essential roles . The embryonic lethality observed in TMEM38A/TMEM38B double knockout mice highlights critical developmental functions that can be further explored using these antibodies .

Within neuroscience research, TMEM38A antibodies are being used to investigate calcium regulation in neuronal tissues, potentially contributing to understanding neurodegenerative disorders characterized by calcium dysregulation . Musculoskeletal research represents another expanding application area, with TMEM38A antibodies enabling detailed studies of excitation-contraction coupling and muscle physiology . These antibodies facilitate examination of TMEM38A's interactions with junctophilin proteins and ryanodine receptors, advancing our understanding of muscle function and disorders . In the realm of immunology, emerging research explores TMEM38A's correlations with immune cell populations and checkpoint molecules, suggesting previously unrecognized immunomodulatory functions . Finally, in the broader field of calcium signaling research, TMEM38A antibodies enable detailed characterization of its role as a counter-ion channel supporting calcium release from intracellular stores, with implications for numerous physiological and pathological processes . These diverse applications highlight the expanding utility of TMEM38A antibodies across multiple scientific disciplines.

How do the functions of TMEM38A at the molecular level influence its research applications?

At the molecular level, TMEM38A functions primarily as a trimeric intracellular cation (TRIC) channel that facilitates counter-ion movements during calcium release from intracellular stores . This fundamental function has profound implications for its research applications across multiple biological contexts. In muscle physiology research, TMEM38A's role in supporting efficient ryanodine receptor-mediated calcium release makes it a critical target for studying excitation-contraction coupling mechanisms . The protein's ability to act in conjunction with junctophilins to maintain proper calcium handling machinery organization further expands its relevance to muscle function and dysfunction studies . Within cardiac research specifically, the embryonic cardiac failure observed in TMEM38A/TMEM38B double knockout mice underscores its essential role in heart development and function, directing research applications toward developmental cardiology and arrhythmia mechanisms .

TMEM38A's emerging role in cancer radiotherapy sensitivity opens new avenues for translational research . The negative correlation observed between TMEM38A expression and the PI3K/AKT/mTOR pathway suggests potential mechanistic links to well-established cancer signaling networks, guiding research toward understanding how calcium handling proteins influence treatment response . The protein's associations with reactive oxygen species pathways, E2F targets, G2M checkpoint regulation, and mitotic spindle formation further expand its research applications to fundamental cancer biology questions regarding cell cycle control and division . TMEM38A's unexpected correlations with immune cell infiltration and immune checkpoint molecules reveal potential immunomodulatory functions that bridge calcium signaling research with tumor immunology . At a technical level, the protein's localization to specific membrane compartments (sarcoplasmic/endoplasmic reticulum) necessitates specialized experimental approaches for its study, including membrane protein extraction protocols, subcellular fractionation, and specific detection methods . Finally, its apparent tissue-specific expression patterns and functions direct research applications toward understanding context-dependent roles across different cell types and physiological states .